UCB's Global Corporate Website

Nayzilam®

Logo Nayzilam

In the U.S., Nayzilam® is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

Related website

Nayzilam® product website (for US residents only)
www.nayzilam.com

Back to our products